Daunorubicin
Links shared publicly online about this topic
Secondary AML Patients Show No Increased Benefit by Adding Amonafide Instead of Daunorubicin in Cytarabine-Based Therapy - MPR
empr.com — “The combination of amonafide + cytarabine does not provide a complete response benefit over treatment with daunorubicin + cytarabine in patients with secondary acute myeloid leukemia, according to a presentation at the American Society of Clinical Oncology’s 2011 Annual Meeting.” View full resource at empr.com
Most Recently Shared on June 3, 2011 at 9:34 pm By:
MPR News: Secondary AML Patients Show No Increased Benefit by Adding Amonafide Instead of Daunorubicin in Cytara... http://bit.ly/lMFLoM
Celator® Pharmaceuticals Presents Data On Combining CPX-351 With Clofarabine Or Azacytidine At The European Hematology Association Congress
medicalnewstoday.com — “Celator Pharmaceuticals announced that new data from a preclinical leukemia study in mice demonstrate that its lead product, CPX-351 (Cytarabine:Daunorubicin) Liposome Injection, alone or in combi” View full resource at medicalnewstoday.com
Most Recently Shared on July 10, 2010 at 2:04 pm By:
MNT Med Conferences Health News
Celator® Pharmaceuticals Presents Data On Combining CPX-351 With Clofarabine Or Azacytidine At The European Hemato... http://mnt.to/3FXf
Celator(R) Pharmaceuticals Presents Interim Data From Phase 2 Study Of CPX-351 In Newly Diagnosed AML At American Society Of Hematology Meeting
medicalnewstoday.com — “Celator Pharmaceuticals announced that interim safety and efficacy data from its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection” View full resource at medicalnewstoday.com
Most Recently Shared on December 8, 2009 at 5:36 pm By:
MNT Clinical Trials Health News
Celator(R) Pharmaceuticals Presents Interim Data From Phase 2 Study Of CPX-351 In Newly Diagnosed AML At American S... http://bit.ly/5umdYQ
Celator® Pharmaceuticals Completes Enrollment In A Second Phase 2 Trial Of CPX-351 In Acute Myeloid Leukemia
medicalnewstoday.com — “Celator Pharmaceuticals announced that it has completed enrollment in a phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus in” View full resource at medicalnewstoday.com
Most Recently Shared on October 27, 2010 at 2:05 pm By:
Celator® Pharmaceuticals Completes Enrollment In A Second Phase 2 Trial Of CPX-351 In Acute Myeloid Leukemia http://mnt.to/3LLv
Antisoma To Amend ACCEDE Phase III Study Of AS1413
medicalnewstoday.com — “Antisoma announces that, following discussions with fda and trial investigators, it plans to amend the primary endpoint in the accede study of as1413. the accede study is an ongoing randomised, co” View full resource at medicalnewstoday.com
Most Recently Shared on October 9, 2009 at 1:47 am By:
Antisoma To Amend ACCEDE Phase III Study Of AS1413: Antisoma announces that, following discussions with FDA and.. http://bit.ly/242QB8
Celator Pharmaceuticals Presents Positive Data from Phase 2 Study of CPX-351 at the American Society of Hematology Annual Meeting - Drugs.com MedNews
drugs.com — “CPX-351 produced higher remission rates, reduced early mortality, with improvements in event-free survival and overall survival in elderly patients with newly-d” View full resource at drugs.com
Most Recently Shared on December 7, 2010 at 2:12 pm By:
Drugs and Devices OW OW Health
Celator Pharmaceuticals Presents Positive Data from Phase 2 Study of CPX-351 at the American Society of He... http://bit.ly/dGWN9K #drug
Oncology Article |
mdlinx.com — “First-in-man study of CPX-351: A liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia” View full resource at mdlinx.com
Most Recently Shared on February 10, 2011 at 6:42 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
First-in-man study of CPX-351: A liposomal carrier containing cytarabine and daunorubicin in a fixed 5... http://bit.ly/eUYo1V #oncology
Phase 2 study of CPX-351 for the treatment of acute myeloid leukemia (AML) - MPR
empr.com — “Celator announced the completed enrollment of its Phase 2 study of CPX-351 (cytarabine and daunorubicin) Liposome Injection for the treatment of adult patients with acute myeloid leukemia (AML).” View full resource at empr.com
Most Recently Shared on October 27, 2010 at 8:26 pm By:
MPR News: Phase 2 study of CPX-351 for the treatment of acute myeloid leukemia (AML): Celator announced the comple... http://bit.ly/b6ewo5
Phase 2 study of CPX-351 for the treatment of acute myeloid leukemia (AML) - MPR
empr.com — “Celator Pharmaceuticals announced results from its Phase 2 trial of CPX-351 (cytarabine and daunorubicin) Liposome Injection for the treatment of adult patients with acute myeloid leukemia (AML).” View full resource at empr.com
Most Recently Shared on December 8, 2010 at 6:26 pm By:
MPR News: Phase 2 study of CPX-351 for the treatment of acute myeloid leukemia (AML): Celator Pharmaceuticals an... http://bit.ly/ejZDj3
Interim data from Celator Pharmaceuticals' CPX-351 trial presented at the ASH meeting
news-medical.net — “Celator Pharmaceuticals today announced that interim safety and efficacy data from its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus conventional cytarabine and daunorubicin therapy ("7+3") in patients 60-75 years of age with untreated acute myeloid leukemia (AML) were presented at the 51st American Society of Hematology (ASH) Annual Meeting in New Orleans, Louisiana (ASH Abstract # 1033).” View full resource at news-medical.net
Most Recently Shared on December 7, 2009 at 2:26 pm By:
Interim data from Celator Pharmaceuticals' CPX-351 trial presented at the ASH meeting: Celator Pharmaceuticals toda... http://bit.ly/6ThC4N
Celator gains $20M round for cancer drug dev - FierceBiotech
fiercebiotech.com — “Princeton, NJ-based Celator Pharmaceuticals has closed a $20 million Series D to back its development work on new cancer therapies. Its lead drug--CPX-351 (Cytarabine:Daunorubicin) Liposome Read more...” View full resource at fiercebiotech.com
Most Recently Shared on September 1, 2010 at 4:21 pm By:
Celator gains $20M round for cancer drug dev. http://bit.ly/dsFkfw
INS cites FDA-approved Totect antidote for anthracycline extravasations
news-medical.net — “The third edition of Infusion Nursing: An Evidence-Based Approach, published by the Infusion Nurses Society (INS), includes Totect(®), the only FDA-approved treatment for anthracycline extravasation. Anthracyclines are a group of chemotherapy medications including daunorubicin, doxorubicin, idarubicin and epirubicin that have been used in the treatment of various types of cancer since the early 1970s.” View full resource at news-medical.net
Most Recently Shared on December 15, 2009 at 6:59 pm By:
Pregnancy News: INS cites FDA-approved Totect antidote for anthracycline extravasations: The third edition of Infus... http://bit.ly/6noU90
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
MPR
eMPR.com provides up-to-date, concise drug information at the point-of-care.
-
MNT Med Conferences
The latest medical conferences news published daily. Articles from research centers, universities and prestigious journals.
-
MNT Clinical Trials
The latest clinical trials news published daily. Articles from research centers, universities and prestigious journals.
Advertisement
